Perha Pharmaceuticals

Executive Summary

Perha Pharmaceuticals is a French biotechnology company founded in 2011 and headquartered in Strasbourg, specializing in the development of small molecule therapeutics that target protein-protein interactions (PPIs). This class of targets has historically been challenging, but Perha’s approach aims to modulate critical intracellular signaling pathways implicated in oncology and inflammatory diseases. By disrupting specific PPIs, the company seeks to address unmet medical needs in areas where conventional approaches have fallen short. While the company has not disclosed specific pipeline candidates or funding details, its focus on PPI inhibitors positions it within a rapidly evolving field with significant therapeutic potential. Perha’s strategy leverages deep expertise in structural biology and medicinal chemistry to design selective and potent small molecules, offering a differentiated approach to drug discovery. The company’s location in Strasbourg, a prominent European biotech hub, provides access to a skilled talent pool and collaborative research networks.

Upcoming Catalysts (preview)

• Q3 2026Series A or B Financing Round60% success
• Q4 2026Initiation of First-in-Human Phase 1 Trial40% success
• Q2 2026Research Collaboration or Licensing Deal50% success